LabReflex

LabReflex
Three Forces Shaping the Lab This Week: Tariffs, Digital Pathology, and Genome First Care

This week’s episode connects three very different headlines that all land directly inside the clinical laboratory. We discuss a Supreme Court ruling on tariffs, a major digital pathology deployment, and a new clinical whole genome sequencing initiative for pediatric rare disease. On the surface, these topics seem unrelated. In practice, they all affect how laboratories operate, spend, and plan for the future.

We begin with the recent Supreme Court decision striking down certain Trump era tariffs that had been implemented under the International Emergency Economic Powers Act. US Customs has stopped collecting the affected tariffs, but the situation around refunds remains uncertain. While trade law may feel distant from everyday lab operations, tariffs directly influence the cost of analyzers, reagents, consumables, and replacement parts. Many laboratory supplies rely on imported components. Even modest trade shifts can create pricing volatility, contract changes, and supply chain disruptions. We discuss what lab leaders should be watching in vendor agreements and procurement planning.

Next, we turn to digital pathology. Labcorp announced an expanded collaboration with PathAI to deploy its FDA cleared digital pathology platform across its anatomic pathology network. This signals that digital pathology is no longer experimental. It is infrastructure. We talk through what this really means operationally, including scanner throughput, storage demands, validation studies, display calibration, IT integration, and ongoing quality oversight. Digital pathology is not simply about scanning slides. It represents a workflow transformation. We also discuss how artificial intelligence tools fit into this landscape and the difference between decision support and automation.

Finally, we examine a new clinical whole genome sequencing initiative in Florida focused on pediatric rare disease. Illumina announced it will provide clinical sequencing and interpretation services to support this program. This reflects a shift toward genome first diagnostic strategies aimed at shortening the diagnostic odyssey for children with complex or undiagnosed conditions. We explore the laboratory implications, including variant interpretation, management of variants of uncertain significance, reanalysis policies, and coordination with clinical teams. Even laboratories that do not perform sequencing in house may feel the impact through changing send out patterns and evolving clinician expectations.

Taken together, these three stories illustrate the pressures shaping modern laboratory medicine. Policy decisions influence cost. Technology reshapes workflow. Genomics alters the test menu and diagnostic strategy. The laboratory is no longer insulated from these broader forces. It sits at the center of them.

If one of these developments is affecting your laboratory, whether through rising costs, digital implementation challenges, or expanding genomics demands, we welcome your perspective and feedback for future episodes.